Bengaluru, October 20, 2020 – Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Ethacrynic Acid Tablets USP, 25 mg from the United States Food & Drug Administration (USFDA). The product is a generic version of Edecrin® Tablets, 25 mg, of Bausch Health Americas, Inc.
Strides Pharma Science Limited on Tuesday announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Ltd, Singapore, has received approval for Ethacrynic Acid Tablets USP, 25 mg from the United States Food & Drug Administration (USFDA).
Strides Pharma Science Limited on Tuesday announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Ltd, Singapore, has received approval for Ethacrynic Acid Tablets USP, 25 mg from the United States Food & Drug Administration (USFDA).nnnRead more a
Enforcement Report - Week of May 27, 2020
Enforcement Report - Week of February 19, 2020
Agnitio`s Generic Ethacrynic Acid Receives Approval in US
Alvogen`s Generic Ethacrynic Acid Receives Approval in US
Zydus Pharms USA’s Generic Ethacrynate Sodium Receives Approval In US
Zydus Cadila has received the final approval from the USFDA to market Ethacrynate Sodium for Inject USP, 50 mg/vial. The drug is used to decrease the swelling (edema) caused by various disease conditions such as liver disease, kidney disease, congestive heart failure, cancer etc. and will be produced at the group's formation manufacturing facility at Moraiya, Ahmedabad.
Par Pharm’s Generic Ethacrynic Acid Receives Approval In US